Balkrishna N. Jahagirdar, MBBS
Investigator, Metro-Minnesota Community Oncology Research Consortium, and Medical Oncologist and Hematologist,
About

Affiliations/other offices held: Assistant professor, Department of Hematology, Oncology and Transplantation, University of Minnesota.

Education and training: MD, Seth G.S. Medical College, India; residency in internal medicine, University of Illinois at Chicago; fellowship in oncology and hematology, University of Minnesota.

Overview/research interests: Dr. Jahagirdar specializes in hematologic malignancies and solid tumors and has a special interest in early (novel) therapeutics and Phase 1 research.

Dr. Jahagirdar is a member of the Experimental Therapeutics Committee of the Alliance for Clinical Trials in Oncology to help design and conduct clinical trials of new cancer treatments throughout the United States, along with his colleagues from Memorial Sloan Kettering Cancer Center, Harvard鈥檚 Dana-Farber Cancer Institute, Mayo Clinic and other institutions. He has co-written a book chapter in the Textbook of Malignant Hematology, and his research is published in such journals as聽Nature, Journal of Clinical Investigation, Blood, Experimental Hematology聽补苍诲听尝别耻办别尘颈补.听

Dr. Jahagirdar is president-elect of the Minnesota Society of Clinical Oncology. In addition, he has received several awards and honors, including the Clinical Excellence Award of University of Minnesota-Regions Hospital, Outstanding Clinical Mentor Awards for training of oncologists-hematologists, the National Cancer Institute鈥檚 MMCCOP-Silver Certificate for contribution to clinical trials in oncology, Alpha-Omega-Alpha Honor Society, University of Minnesota Department of Medicine Fellow Research Award, and the Blood and Marrow Transplant Award.

Affiliation
positions
  • Investigator, Metro-Minnesota Community Oncology Research Consortium, Cancer Research Center
  • Publications While At 开云体育
    selected publications
    Journal Article
  • Association of adiponectin and vitamin D with tumor infiltrating lymphocytes and survival in stage III colon cancer
    JNCI cancer spectrum. 2021
  • Two malignancies with differential responses to immune checkpoint inhibitors: a case report
    Anticancer Research. 2020
  • Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors
    Haematologica. 2019
  • Tailoring a survivorship care plan: patient and provider preferences for recipients of hematopoietic cell transplantation
    Biology of Blood and Marrow Transplantation. 2019
  • Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
    Lancet Oncology. 2018
  • Physical activity and outcomes in patients with stage III colon cancer: a correlative analysis of Phase III Trial NCCTG N0147 (Alliance)
    Cancer Epidemiology, Biomarkers and Prevention. 2018
  • Response to Osimertinib in an EGFR Exon 20 insertion-positive lung adenocarcinoma
    Journal of Thoracic Oncology. 2018
  • Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance)
    Journal of Gastrointestinal Oncology. 2017
  • Quantification of pain in sickle mice using facial expressions and body measurements
    Blood Cells, Molecules, and Diseases. 2016
  • Conference Poster
  • Psychological and spiritual well being of breast cancer survivors in a community-based cancer survivorship clinic [poster]
    2010
  • Contact
    full name
  • Balkrishna N. Jahagirdar, MBBS
  • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration
    More Info